Substituted Fatty Acids for NASH Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-alcoholic steatohepatitis (NASH) have limited efficacy in reversing pronounced histological and inflammatory changes, and omega-3 fatty acids, while beneficial, may not be sufficiently potent to treat established NASH effectively.
Innovation Solution
Administration of a pharmaceutically effective amount of 2-ethyl-2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenylthio)butanoic acid or its derivatives, which reduce hepatic cholesterol levels, inhibit bile acid synthesis, and exhibit anti-inflammatory and anti-fibrotic effects, addressing multiple pathways involved in NASH pathogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If omega-3 fatty acids are administered to treat NASH, then plasma lipid levels and cardiovascular functions are improved, but the treatment is not sufficiently potent to reverse pronounced histological and inflammatory changes in established NASH
Solution Approach 1:
The patent modifies the chemical structure of omega-3 fatty acids by introducing substituents at specific positions (such as ethyl groups at position 2, or hydroxyl groups at position 15) to create derivatives with enhanced pharmacological activity. These structural parameter changes increase the potency of the compounds, enabling them to effectively reverse pronounced histological and inflammatory changes in established NASH that conventional omega-3 fatty acids cannot adequately address.
Solution Approach 2:
The invention creates composite molecular structures by combining the core omega-3 fatty acid backbone (EPA or DHA) with additional functional groups and substituents. This composite approach integrates the beneficial effects of omega-3 fatty acids with enhanced anti-inflammatory and anti-fibrotic properties, resulting in a multi-functional therapeutic agent that addresses multiple pathological features of NASH simultaneously.
2Ease of operation
If current treatments are used for NASH, then some symptomatic relief may be achieved, but they have limited efficacy in reversing pronounced histological and inflammatory changes
Solution Approach 1:
The patent employs systematic modification of molecular parameters including chain length, degree of unsaturation, and substituent types to optimize the therapeutic index of the compounds. These parameter changes enhance the ability of the treatments to reverse histological changes while maintaining acceptable safety profiles and treatment accessibility.
3Reliability
If substituted fatty acid compounds are administered, then hepatic cholesterol levels and inflammation are significantly decreased, but the compound structure becomes more complex
Solution Approach 1:
The patent applies controlled parameter changes to the fatty acid structure, introducing substituents at specific positions rather than throughout the entire molecule. This targeted approach maintains reasonable structural complexity while achieving significant improvements in metabolic and anti-inflammatory efficacy. The modifications are systematic and follow predictable patterns that facilitate understanding and further development.
Data Source
AI summary
The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II):wherein R1, R2, R3, X and Y are as defined in the specification;or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I):wherein R2, R3, and X, are as defined in the specification;or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.Further, the present invention relates to a compound of Formula (I) for preventing and/or treating non-alcoholic steatohepatitis, wherein R2, R3 and X are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.